Tilray Brands (TLRY) Q4 FY26 earnings call: guidance and Q&A

How does the diversified business model (cannabis, beverage, hospitality, wellness) work together as a 'machine' for long-term growth and value creation?

Irwin Simon explained that Tilray has built a diversified global platform with strong brands, manufacturing, and distribution across multiple high-growth consumer categories. He highlighted the potential of cannabis (especially ready-to-drink formats), the established U.S. beverage infrastructure for future THC beverages, the growing European medical cannabis and pharmaceutical distribution business, and the strategic value of BrewDog for international expansion. The interconnected model provides flexibility and resilience, not relying on a single regulatory outcome.

“What Tilray has today is a beverage business in the U.S. It has 8 manufacturing facilities, it has 18 brands. It has a major distribution system. As we know, we have that 3-tier distribution system with 900 distributors. We have a major sales force in place. So we have infrastructure in place for consumer products and ultimately, is it connected with hemp-type products? Is it THC products? And/or is it just consumer products?”

asked by Kaumil Gajrawala · answered by Irwin Simon

Why is full vertical integration the right structure for the medical cannabis side, given the company's infrastructure and choices?

Simon emphasized that vertical integration ensures consistent quality, genetics, and potency, which is crucial for medical cannabis and preferred by customers. It allows for planned R&D and testing, avoiding reliance on spot markets. He cited the U.K. Life acquisition as an example, integrating doctors and pharmacies, and BrewDog for beverage manufacturing and distribution control.

“So, just number one, it's Grow and consistency of Grow. It's the genetics out there. It's the potency and basically from a cost standpoint... We can plan all that out ourselves. So that's very, very important for us.”

asked by Kaumil Gajrawala · answered by Irwin Simon

Q4 organic growth for beverages (excluding BrewDog) was down 17% despite the World Cup. What gives confidence in fixing the underlying beverage brands, especially with BrewDog and Carlsberg contributing next year?

Simon attributed the decline to a major SKU and brand rationalization, eliminating unprofitable businesses. He acknowledged the challenges of integrating multiple acquisitions, facility closings, distributor rationalization, and the overall beer category decline. He expressed confidence in new products, regional focus (Shock Top and Carlsberg as national brands), new operational leadership, and cost-cutting measures to drive growth.

“We went through a major skew rationalization, some brand rationalization. So some of that was basically self-inflicted, and then ultimately, where businesses that we were just not profitable... we have done a major overhaul and with new products, with going through the skew rationalization, with really focusing on certain regional markets and Shock Top and Carlsberg will be our 2 national brands and the rest will be regional brands, we feel good going into this year that we'll get the growth.”

asked by Xin Ma · answered by Irwin Simon

Canadian adult-use growth slowed to 3.2% in Q4 from 9% in Q3. What drove this slowdown, specifically the split between volumes and pricing, and was it due to negative mix or market maturity?

Simon clarified that adult-use cannabis revenue grew 5% (not 3.2%) and the slowdown was primarily due to a strategic decision to deprioritize wholesale supply to focus on higher-margin international markets, not pricing. He noted growth in pre-rolls, chocolate edibles, and vapes, while flower sales were down as the market shifts. Blair MacNeil added that it was 90% mix-driven with a little positive pricing contribution.

“First of all, it was 5% growth on recreational cannabis is number one. Number two, some decisions, again, we make, and that was supply for our international business. We did not supply any wholesalers, and we got away from that. And we focused, and that's why our margins are up, we focused on businesses that are going to contribute margins to us and going to contribute profitable growth instead of just going out there and being in the price competitive market.”

asked by Xin Ma · answered by Irwin Simon

What is the expected quarterly sequencing for EBITDA, especially with BrewDog, and what are the medium-term EBITDA margin aspirations?

Carl Merton stated that the historical sequencing (Q1-Q3 roughly half, Q4 the other half, with Q1-Q3 relatively even) is expected to continue, possibly with a small softening due to BrewDog. Irwin Simon expressed an aspiration for 15% to 18% EBITDA margins for the branded products business over the next couple of years, noting that excluding the lower-margin distribution business would show higher current margins. He also mentioned transforming CC Pharma to improve its margins.

“So my aspiration, and again, you got to look at us from our branded products business... I'd like to see us as a 15% to 18% EBITDA business.”

asked by Aaron Grey · answered by Irwin Simon

If the U.S. reschedules medical and recreational cannabis but maintains state silos without FDA oversight, would Tilray still enter, and how? Or would it wait for interstate commerce and FDA involvement?

Simon stated that Tilray would consider entering major states but expressed concerns about the cost and potential instability if policies change with new administrations. He emphasized the need for a clear, stable regulatory path, ideally with FDA involvement and physician-prescribed models similar to Europe, before making significant investments or acquisitions in the U.S. He reiterated that Tilray is disciplined and will wait for clarity.

“Would we look to enter the big states where there is opportunities? Yes. Would it be more costly? Yes. And again, it's kind of coming back and doing the economics, does it make sense? And I come back and say this here, if it did happen in this administration, would it change in the next administration?”

asked by Pablo Zuanic · answered by Irwin Simon

What drove the improved gross margin in CC Pharma, and how does Tilray plan to transform this business, including its future gross margins?

Irwin Simon attributed the margin improvement to a better mix of medicines, increased footprint in Germany (13k to 16k pharmacies), and better purchasing prices due to available capital. He outlined plans to transform CC Pharma into a licensed cannabis facility for storage, sales, and compounding (e.g., pre-rolls, vapes), and to expand its format into other European countries (U.K., Italy) and potentially direct-to-consumer medical services. Rajnish Ohri added that it involves portfolio management, effective capital allocation, and focusing on high-value cannabis businesses. Simon noted the potential to increase gross margins by another 5-7 points.

“The big growth there is having different medicines to supply and growing our footprint in Germany from 13,000 drugstores to 16,000 drugstores. Our gross margin improved 14% and that's just a good array of mix... one of the big things that we're looking at CC Pharma is having CC Pharma as a licensed cannabis facility that can store and sell cannabis, at the same time, can become a compounder.”

asked by Brenna Cunnington · answered by Irwin Simon

How does Tilray expect its international cannabis business to grow after 34% growth in FY26, and how will it protect margins with full Portugal facility capacity?

Simon explained that growth will come from increased supply (where there were shortages), faster permit approvals in Europe, and the growing demand for medical cannabis. He highlighted the Life acquisition in the U.K. (integrating doctors and pharmacies) and potential expansion into new markets like India. Despite price compression, the company managed to deal with it, implying that scale and vertical integration help protect margins.

“So, a big part of the growth is having supply where we did not have supply throughout last year. The second part is, you know, we've really worked with both the Portuguese government, the German government, and other governments not to depend upon delay of permits... The next thing is this here, just the demand, for medical cannabis in these countries continues to grow.”

asked by Indigo Baylis · answered by Irwin Simon